DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

India - English

• USA - English

BOSTON, Jan. 8, 2019 /PRNewswire/ -- DPS Group, a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, announced today that it has been selected to design two cGMP manufacturing facilities for Brammer Bio, an industry leading viral vector contract development and manufacturing organization (CDMO).

Brammer engaged DPS Group to provide process architecture and engineering services for the design of commercial suites that produce multiple gene transfer vector products in support of late-stage clinical programs leading to commercial supply. DPS Group is designing advanced gene therapy manufacturing suites for Brammer in Cambridge and a state-of-the-art gene therapy facility in Lexington, Mass. These manufacturing facilities will enable Brammer to optimize facility footprint and flexibility by accommodating a range of processes and products, while addressing scalability and capacity. Both projects have accelerated schedules for design and construction and are expected to be complete in the first half of 2019.

"Flexibility in facility design is essential to meet the diverse processing needs of our biopharmaceutical clients, who trust us to advance their research and accelerate the delivery of medicines to improve patient health," said Mark Bamforth, President and CEO of Brammer Bio. "DPS Group brings an in-depth understanding of established cGMP manufacturing methods and experience with the challenges in implementing emerging biological technologies. Working with us on the Cambridge and Lexington projects, DPS Group has fostered a culture of collaboration to incorporate best practices and consistency in the facility designs."

Cambridge, Mass.
DPS Group is designing an 8,000 SF renovation of Brammer's commercial cGMP facility located in Cambridge, Mass. Part of a larger 66,000 SF building, the new space will increase the number of commercial suites, providing Brammer with additional capacity to produce treatments for a wider array of biotech companies.

Lexington, Mass.
DPS Group is providing detailed design services to assist Brammer in developing a new cGMP manufacturing and quality control (QC) operations facility in an existing 50,000 SF building in Lexington, Mass. As the company's second commercial facility, the 35,000 SF build-out will support cGMP viral vector manufacturing. DPS Group's design affiliate TRIA, a partner-led architecture firm, is designing a 15,000 SF office space as the second phase of the Lexington facility.

About DPS Group
DPS Group is a global engineering, consulting and project management company, serving high-tech industries around the world. For more information, visit www.dpsgroupglobal.com.

About Brammer Bio
Brammer Bio provides clinical and commercial supply of vectors for in vivo gene therapy and ex vivo modified-cell based therapy, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. For more information, visit www.brammerbio.com.

SOURCE DPS Group

Related Links

http://www.dpsgroupglobal.com